589 related articles for article (PubMed ID: 30604091)
1. Lilly Insulin Glargine Versus Lantus
Pollom RK; Ilag LL; Lacaya LB; Morwick TM; Ortiz Carrasquillo R
Diabetes Ther; 2019 Feb; 10(1):189-203. PubMed ID: 30604091
[TBL] [Abstract][Full Text] [Related]
2. Lilly Insulin Glargine Versus Lantus
Mohan V; Ahn KJ; Cho YM; Sahay RK; Huang CN; Kalra S; Chadha M; Bhattacharya I; Kim SY; Spaepen E
Clin Drug Investig; 2019 Aug; 39(8):745-756. PubMed ID: 31119716
[TBL] [Abstract][Full Text] [Related]
3. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).
Rosenstock J; Hollander P; Bhargava A; Ilag LL; Pollom RK; Zielonka JS; Huster WJ; Prince MJ
Diabetes Obes Metab; 2015 Aug; 17(8):734-41. PubMed ID: 25931141
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial.
Feng W; Chen W; Jiang S; Du L; Zhu D
Diabetes Obes Metab; 2021 Aug; 23(8):1786-1794. PubMed ID: 33783964
[TBL] [Abstract][Full Text] [Related]
5. Similar Efficacy and Safety of Basaglar
Pollom RK; Costigan T; Lacaya LB; Ilag LL; Hollander PA
Diabetes Ther; 2018 Apr; 9(2):827-837. PubMed ID: 29542012
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.
Blevins TC; Dahl D; Rosenstock J; Ilag LL; Huster WJ; Zielonka JS; Pollom RK; Prince MJ
Diabetes Obes Metab; 2015 Aug; 17(8):726-33. PubMed ID: 25974640
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus
Yan X; Feng C; Lou Y; Zhou Z
Diabetes Ther; 2022 Jun; 13(6):1161-1174. PubMed ID: 35471721
[TBL] [Abstract][Full Text] [Related]
8. Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial.
Yan X; Jiang S; Lou Y; Zhou Z
Diabetes Obes Metab; 2021 Oct; 23(10):2226-2233. PubMed ID: 34121308
[TBL] [Abstract][Full Text] [Related]
9. Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus
Nishiyama H; Shingaki T; Suzuki Y; Ilag LL
Diabetes Ther; 2018 Aug; 9(4):1469-1476. PubMed ID: 29855972
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus
Ilag LL; Costigan TM; Deeg MA; Pollom RK; Chang CL; Konrad RJ; Prince MJ
Diabetes Ther; 2017 Jun; 8(3):545-554. PubMed ID: 28361463
[TBL] [Abstract][Full Text] [Related]
11. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Yang W; Dong X; Li Q; Cheng Z; Yuan G; Liu M; Xiao J; Gu S; Niemoeller E; Chen L; Ping L; Souhami E;
Diabetes Obes Metab; 2022 Aug; 24(8):1522-1533. PubMed ID: 35441412
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine.
Hadjiyianni I; Dahl D; Lacaya LB; Pollom RK; Chang CL; Ilag LL
Diabetes Obes Metab; 2016 Apr; 18(4):425-9. PubMed ID: 26749289
[TBL] [Abstract][Full Text] [Related]
14. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.
Halberg IB; Lyby K; Wassermann K; Heise T; Zijlstra E; Plum-Mörschel L
Lancet Diabetes Endocrinol; 2019 Mar; 7(3):179-188. PubMed ID: 30679095
[TBL] [Abstract][Full Text] [Related]
16. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial.
Onishi Y; Ono Y; Rabøl R; Endahl L; Nakamura S
Diabetes Obes Metab; 2013 Sep; 15(9):826-32. PubMed ID: 23557077
[TBL] [Abstract][Full Text] [Related]
17. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
18. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
[TBL] [Abstract][Full Text] [Related]
19. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.
Linnebjerg H; Lam EC; Zhang X; Seger ME; Coutant D; Chua L; Kapitza C; Heise T
Diabetes Obes Metab; 2017 Jan; 19(1):33-39. PubMed ID: 27484286
[TBL] [Abstract][Full Text] [Related]
20. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
Rosenstock J; Aronson R; Grunberger G; Hanefeld M; Piatti P; Serusclat P; Cheng X; Zhou T; Niemoeller E; Souhami E; Davies M;
Diabetes Care; 2016 Nov; 39(11):2026-2035. PubMed ID: 27527848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
